Aimmune Therapeutics, Inc. — Form D

Aimmune Therapeutics, Inc. of BRISBANE, CA, a company, filed a Form D exempt-offering notice with the SEC on 2018-11-29. The offering totals $98.0M, of which $98.0M was reported sold. Industry: Other Health Care.

Offering

Issuer

Officers, directors & promoters (21)

NameRoleLocation
Gregory E BeharDirectorBrisbane, CA
Jayson DA DallasDirectorBrisbane, CA
Patrick G EnrightDirectorSan Diego, CA
Kathryn E FalbergDirectorNew York, NY
Brett K HaumannDirectorBrisbane, CA
Mark T IwickiDirector3584 CM Utrecht, P7
Mark D McDadeDirectorMenlo Park, CA
Stacey D SeltzerDirectorBrisbane, CA
Daniel C AdelmanExecutive OfficerBrisbane, CA
Susan E BarrowcliffeExecutive OfficerBrisbane, CA
Eric H BjerkholtExecutive OfficerBrisbane, CA
Jayson DA DallasExecutive OfficerBrisbane, CA
Mary M RozenmanExecutive OfficerBrisbane, CA
Douglas T SheehyExecutive OfficerBrisbane, CA
Jeffrey H KnappExecutive OfficerBrisbane, CA
Stephen G Dilly, Jr.DirectorBrisbane, CA
Stephen G Dilly, Jr.Executive OfficerBrisbane, CA
Joonkyoo (Anthony) L YunDirectorSan Mateo, CA
James D TananbaumDirectorSan Francisco, CA
Victor G ColungaExecutive OfficerSan Mateo, CA
Bryan L WalserDirectorSan Mateo, CA

Other filings by this issuer (2)

FiledFormOfferingSold
2018-03-16D$156.7M$156.7M
2015-03-24D$80.0M$80.0M

More